12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MEK162: Phase III started

Array began the open-label, international Phase III MILO trial to compare 45 mg oral MEK162 twice daily vs. investigator's choice of chemotherapy in about 300 patients following >=1 platinum-based chemotherapy regimen and <=3 lines of chemotherapy. The start...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >